Blog
RSS FeedPosted by Michael Wonder on 20 Sep 2019
Addition of Kisqali to drug plan in Quebec expands access to treatment for metastatic breast cancer
19 September 2019 - Provincial reimbursement provides public access to treatment that may delay the progression of advanced breast cancer. ...
Posted by Michael Wonder on 18 Sep 2019
Baby Pia: almost 1 million Belgians pay for life-saving drug
18 September 2019 - More than 950,000 Belgians have responded to a couple seeking €1.9m ($2m; £1.7m) to cover the ...
Posted by Michael Wonder on 18 Sep 2019
Three-year-old Matilda's ability to walk is giving hope to those with spinal muscular atrophy
18 September 2019 - The disease, which has been described as motor neurone disease for children, is the leading cause of ...
Posted by Michael Wonder on 18 Sep 2019
'A child's health should not be a postcode lottery': anger of cystic fibrosis sufferers forced to pay £20,000 for drug abroad
17 September 2019 - Patients have formed a buyers' club to source a version of Orkambi after the drug's manufacturer and ...
Posted by Michael Wonder on 17 Sep 2019
News NHS England explores funding options for cystic fibrosis drug
17 September 2019 - NHS England is “committed to exploring and developing alternative routes” to enable people with cystic fibrosis ...
Posted by Michael Wonder on 16 Sep 2019
Canada decides: Leading parties plan to tackle ways to make medicine affordable
16 September 2019 - Canadian voters will be hearing a lot about a new national prescription drug program to fill a ...
Posted by Michael Wonder on 14 Sep 2019
Right to try ‘remains a bust,’ as many drug makers prefer FDA reviews
12 September 2019 - Despite the hubbub over the “right-to-try” law, a recent survey found that nearly half of drug ...
Posted by Michael Wonder on 14 Sep 2019
The U.S. health care system found a way to make peanuts cost $4,200
13 September 2019 - A new, billion-dollar pharmaceutical to treat peanut allergies is up for approval. It’s simply peanut flour. ...
Posted by Michael Wonder on 13 Sep 2019
Vertex announces new access agreement with Scottish Government for Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor)
12 September 2019 - Eligible patients in Scotland will immediately have access to Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor) in combination with ...
Posted by Michael Wonder on 13 Sep 2019
Medexus reports Health Quality Ontario recommends Gliolan for public reimbursement
12 September 2019 - Medexus Pharmaceuticals today announced that Health Quality Ontario, under the guidance of the Ontario Health Technology ...
Posted by Michael Wonder on 12 Sep 2019
Batten disease treatment: parents win battle ahead of court date
11 September 2019 - Families of children with a rare degenerative disease have won their fight for funding for NHS ...
Posted by Michael Wonder on 12 Sep 2019
In U.S. biosimilars run into more roadblocks
12 September 2019 - In a recent op-ed in the Wall Street Journal Peter Bach asks whether it's time to ...
Posted by Michael Wonder on 12 Sep 2019
Public plans covered only 26% of the 491 new drugs approved by Health Canada from 2009 to 2018; national pharmacare is an empty promise for 23.2 million Canadians now covered by private plans
11 September 2019 - Two new studies confirm the abysmal state of access to innovative medicines in Canada’s publicly funded drug ...
Posted by Michael Wonder on 12 Sep 2019
New rules will keep the best medications from desperate Canadians
12 September 2019 - One reaction to recent amendments to the rules of the federal Patented Medicine Prices Review Board, ...
Posted by Michael Wonder on 11 Sep 2019
Immunotherapy a groundbreaking new cancer treatment, but prohibitively expensive
10 September 2019 - Dave Roberts is fighting for his life, and his doctor says there is only one option ...